Abbott Laboratories (ABT)
NYSEHealth CareMedical DevicesSnapshot 2026-07-08
$95.09-0.78%
Close 2026-07-08 · 1-day change
Reading ABT? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ABT free→NYSEHealth CareMedical DevicesSnapshot 2026-07-08
Reading ABT? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ABT free→Warn: Management is running behind on a stated commitment.
Abbott aims for 6.5% to 7.5% organic sales growth in 2026. Adjusted EPS is guided around $5.48 per share for 2026. The company cleared a major legal risk, reducing uncertainty. Abbott's acquisition of Exact Sciences supports growth in oncology diagnostics.
Abbott faces a lawsuit over PediaSure that could hurt sales and reputation. EPS growth may be pressured by acquisition dilution and soft guidance. Revenue growth below 6.5% would challenge management's targets.
The price is about 15% below our fair value near $112. Analysts expect roughly 14% revenue growth, which is slightly above management's 6.5% to 7.5% organic growth target. Our fair value is 6% below the Street median, reflecting some caution.
Breaks if: EPS falls below $5.12 in FY26
Focus on achieving EPS growth while managing the dilution impact from the Exact Sciences acquisition.
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 4 of last 4 quarters. Adjusted diluted EPS grew from $1.09 in 2025-Q1 to $1.15 in 2026-Q1. The trajectory indicates progress towards achieving EPS growth despite acquisition-related dilution.
“Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences.”
“Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which reflects growth of 10 percent at the midpoint.”
“Abbott reaffirms the midpoint of previously provided full-year 2025 adjusted diluted EPS guidance range.”
“Abbott projects full-year 2025 adjusted diluted EPS of $5.10 to $5.20, which reflects double-digit growth at the midpoint.”
Breaks if: Failure to realize synergies or integration setbacks reported
Focus on integrating Exact Sciences to realize synergies and strengthen the oncology diagnostics market position.
Breaks if: Legal rulings cause significant financial or reputational damage
Breaks if: Organic revenue growth falls below 6.5% in FY26
Focus on integrating Exact Sciences to realize synergies and strengthen the oncology diagnostics market position.
Focus on achieving organic sales growth of 6.5% to 7.5% for the full year 2026.
Stated in 6 of last 6 quarters. Revenue grew from $10.358 billion in 2025-Q1 to $11.164 billion in 2026-Q1. The trajectory shows delivering on the stated growth target.
“Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%.”
“Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%.”
“Abbott reaffirms previously provided full-year 2025 organic sales growth guidance.”
“Abbott projects full-year 2025 organic sales growth, excluding COVID-19 testing-related sales, to be 7.5% to 8.0%.”
“Abbott reaffirms all previously provided full-year 2025 financial guidance.”
“Abbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5%.”